163 related articles for article (PubMed ID: 34302042)
1. Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA.
Pan J; Chen Y; Zhang Q; Khatun A; Palen K; Xin G; Wang L; Yang C; Johnson BD; Myers CR; Sei S; Shoemaker RH; Lubet RA; Wang Y; Cui W; You M
Commun Biol; 2021 Jul; 4(1):906. PubMed ID: 34302042
[TBL] [Abstract][Full Text] [Related]
2. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers.
Wakiyama H; Furusawa A; Okada R; Inagaki F; Kato T; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Dec; 71(12):2869-2879. PubMed ID: 35445836
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.
Schaafsma E; Croteau W; ElTanbouly M; Nowak EC; Smits NC; Deng J; Sarde A; Webber CA; Rabadi D; Cheng C; Noelle R; Lines JL
Cancer Immunol Res; 2023 Jan; 11(1):38-55. PubMed ID: 36260656
[TBL] [Abstract][Full Text] [Related]
5. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.
Huang M; Xiong D; Pan J; Zhang Q; Sei S; Shoemaker RH; Lubet RA; Montuenga LM; Wang Y; Slusher BS; You M
Adv Sci (Weinh); 2022 Sep; 9(26):e2105885. PubMed ID: 35861366
[TBL] [Abstract][Full Text] [Related]
6. VISTA Regulates the Development of Protective Antitumor Immunity.
Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
[TBL] [Abstract][Full Text] [Related]
7. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
[TBL] [Abstract][Full Text] [Related]
8. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
9. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.
Tchekneva EE; Goruganthu MUL; Uzhachenko RV; Thomas PL; Antonucci A; Chekneva I; Koenig M; Piao L; Akhter A; de Aquino MTP; Ranganathan P; Long N; Magliery T; Valujskikh A; Evans JV; Arasada RR; Massion PP; Carbone DP; Shanker A; Dikov MM
J Immunother Cancer; 2019 Apr; 7(1):95. PubMed ID: 30940183
[TBL] [Abstract][Full Text] [Related]
10. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
11. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
12. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
13. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
[TBL] [Abstract][Full Text] [Related]
14. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
15. Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice.
Sergent PA; Plummer SF; Pettus J; Mabaera R; DeLong JK; Pechenick DA; Burns CM; Noelle RJ; Ceeraz S
Lupus; 2018 Feb; 27(2):210-216. PubMed ID: 28659048
[TBL] [Abstract][Full Text] [Related]
16. Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).
Wang T; Wang K; Zhang Y; Zhang K; Cai S; Jiang S; Xiao Y; Zhang X
J Med Chem; 2023 Sep; 66(17):11881-11892. PubMed ID: 37594853
[TBL] [Abstract][Full Text] [Related]
17. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
18. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
19. CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells.
Zhang Y; Hu J; Ji K; Jiang S; Dong Y; Sun L; Wang J; Hu G; Chen D; Chen K; Tao Z
Cell Rep Med; 2023 Aug; 4(8):101151. PubMed ID: 37567173
[TBL] [Abstract][Full Text] [Related]
20. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
